Skip to main content

Table 4 Treatment results of selected series of GBM and GBMO

From: Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

series

patient group

n

treatment

median overall survival (months)

2-year overall survival

reference

NOA-01

all GBM

154

post-OP RT + ACNU/VM26

17.3

25%

[7]

EORTC 26981

all GBM

287

post-OP RT + TEM

14.6

26.5%

[5]

RTOG 83-02

GBMO

23

post-OP RT + BCNU

14.3

(3-year survival: 35%)

[4]

retrospective

GBMO

12

resection + RT, chemo in 2/12

26

58% (data taken from graph)

[8]

retrospective

GBMO

11

post-OP RT in 65% (total group)

17.7

20% (data taken from graph)

[18]

retrospective

GBMO

5

post-OP RT in 80%

16.2

n. a.

[19]

present series

GBMO

10

post-OP RT + ACNU/VM26 (8/10)

26

60%

 
  1. Overview of treatment results in glioblastoma multiforme (GBM) and GBM with oligodendroglial component (GBMO) from selected series (RT: radiotherapy, ACNU: nimustine, VM26: teniposide, TEM: temozolomide, n. a.: not available).